Chapter 13. Pricing of Pharmaceuticals

  1. Nick Freemantle1 and
  2. Suzanne Hill2
  1. David Newby,
  2. Andrew Creese and
  3. Alan Stevens

Published Online: 5 NOV 2007

DOI: 10.1002/9780470994719.ch13

Evaluating Pharmaceuticals for Health Policy and Reimbursement

Evaluating Pharmaceuticals for Health Policy and Reimbursement

How to Cite

Newby, D., Creese, A. and Stevens, A. (2004) Pricing of Pharmaceuticals, in Evaluating Pharmaceuticals for Health Policy and Reimbursement (eds N. Freemantle and S. Hill), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470994719.ch13

Editor Information

  1. 1

    Department of Primary Care and General Practice, University of Birmingham,Birmingham,UK

  2. 2

    Faculty of Health,University of Newcastle,Newcastle, Australia

Publication History

  1. Published Online: 5 NOV 2007
  2. Published Print: 1 AUG 2004

ISBN Information

Print ISBN: 9780727917843

Online ISBN: 9780470994719

SEARCH

Keywords:

  • drug costs;
  • new medicines;
  • reference based pricing;
  • pharmaceutical industry;
  • ACE inhibitors

Summary

This chapter contains sections titled:

  • Introduction

  • Market failure in the pharmaceutical sector

  • Approaches to pricing new medicines

  • Reference based pricing

  • Performance based pricing: pharmacoeconomics

  • Differential pricing

  • Average/comparative pricing

  • Profit control

  • Tendering

  • Other pricing methods for new drugs

  • Other methods to control pharmaceutical prices

  • Taxes and duties

  • Wholesaler and dispensing margins

  • Role of generics

  • Conclusion

  • References